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but these laws are neither universal nor consistent. This study estimates the hospital-
wide prevalence, cost, and mortality of CLABSI-associated discharges for all US 
community hospitals. Hypotheses are that CLABSI prevalence and mortality are 
increasing and cost is unchanged. METHODS: Data for the study was extracted from 
the AHRQ HCUP National Inpatient Sample (NIS) database for 2002 and 2006. 
CLABSI was deﬁned as a discharge with an ICD9-CM procedure code for a central 
line procedure (38.92, 38.93, and 38.95) and an ICD9-CM diagnosis code for a 
BSI (24 codes). SAS Proc Surveyreg was used to estimate (log of) cost, and Surveylo-
gistic was used to estimate mortality and CLABSI prevalence. NIS weights were used 
to make national estimates, charges were adjusted using cost-to-charge ratios, and 
costs were adjusted to 2006 US dollars using the hospital service CPI. RESULTS: 
Average cost of a CLABSI-related hospitalization was $31,879 in 2006 dollars. Pres-
ence of CLABSI had a positive signiﬁcant effect on cost (0.128, p  0.001), as did the 
number of procedures (0.125, p  0.001) and LOS (0.034, p  0.001) while being 
female had a signiﬁcant negative effect (0.027, p  0.001). The time variable was not 
signiﬁcant (0.056, p  0.052). OR for CLABSI increased over time (1.196, p  0.001) 
when controlling for gender, LOS, number of procedures, liver disease, and renal 
failure. For mortality signiﬁcant ORs (p  0.001) were time (0.761), female (0.875), 
LOS (0.982), age (1.026), number of procedures (1.204), liver disease (1.814), 
and CLABSI (2.348). CONCLUSIONS: CLABSI-related hospital mortality in the 
US is decreasing as is the cost of treatment. However, the prevalence of CLABSI is 
increasing.
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THOUGHTS ON THE LABORATORY CULTURES REIMBURSED BY  
THE SOCIAL SECURITY IN AUSTRIA (OUTPATIENT SECTOR IN 
PHYSICIANS’ CARE AND INSTITUTES, BUT NOT HOSPITAL 
OUTPATIENT CARE)
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OBJECTIVES: If a patient shows an infection, the physician has to decide which kind 
of anti-infective substance has to be prescribed. One method to ﬁgure this out is to 
order laboratory cultures. We want to ﬁnd out whether there is a correlation between 
the frequencies of cultures reimbursed and the number of prescriptions of anti-infective 
agents. METHODS: Claims data (2006) from physicians in free practice and institutes 
for laboratory medicine data for laboratory cultures were conducted out of different 
reimbursement catalogs in Austria. RESULTS: The rate of reimbursed cultures per 
prescription was 11% (for bacterial cultures and antibacterial medication J01, J04), 
63% (for mycotic cultures and antimycotic medication J02), 24% for viral cultures 
and antiviral medication J05) and 25% (for parasitic cultures and antiparasitical 
medication P01,02,03). If just those infections veriﬁed by cultures had caused a pre-
scription, the costs for anti-infective agents would have been 17% of the current 
number. If all prescriptions for anti-infective agents had been based on a culture, the 
prescription costs would have been 7,5 times higher. There are price differences for 
cultures due to various contract partners. If the lowest fee had been paid for each test 
we would have saved 33% of the current turnover for bacterial, 37% for mycotic, 
38% for viral, and 6% for parasitic infections. If the highest price had been paid we 
would have paid 75% (bacterial), 46% (mycotic), 164% (viral) and 33% (parasitic) 
more than the current turnover. CONCLUSIONS: Our further research will focus on 
the different categories of prescription for anti-infective agents, testing and also the 
guideline conformity of its use.
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DIRECT MONTHLY HAART SUPPLY AT THE AIDS CENTER— 
A COST-EFFECTIVE MODE TO INCREASE ADHERENCE AND OUTCOME
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OBJECTIVES: To determine the cost effectiveness of direct monthly supply of 
HAART (Highly active anti retroviral therapy) medications at the AIDS center. 
METHODS: We analyzed 385 HIV patients, mostly (90%) immigrants from Africa 
(HIV subtype C) that were treated with HAART for more than one year prior to the 
initiation of the study. During the ﬁrst two years of the study, all patients received 
HAART prescriptions and the medications were supplied by local pharmacies. There-
after (next 2 years) all patients received their medications, monthly, by a nurse (on a 
part-time job basis) at our AIDS center. Compliance, immunological (CD4) and viro-
logical (VL) outcome between the two study periods (modes) were compared. 
RESULTS: The mean age of our patients, 48% males, at time of study initiation was 
35 o 13 (mean o SD) years. The mean time from HIV diagnosis was 7.3 o 4.1 years. 
Following the ﬁrst 2 years, 75% of the patients attended more then 90% of scheduled 
visits with 57% treatment adherence (90% of prescriptions). The mean CD4 count 
at the end of this period was 324.8 o 220.9 cell/mcl (66.7%  200 cells/mcl). Virologi-
cal failure (VL  40 copies/ml) was observed in 53% (mean VL 182,918 o 834,916 
copies/ml) of the treated patients. As a result of our intervention (two years of direct 
HAART supply), visits and treatment compliance increased, signiﬁcantly (p  0.001), 
to 90% and 84%, respectively. Concomitantly the CD4 cell counts increased to 470 
o 266 cell/mcl (p  0.24 compared to the ﬁrst study period) with 83.6% CD4 counts 
200 cells/mcl (p  0.001). A low rate of virological failures (28%; p  0.001; mean 
VL 15,068 o 73,382 copies/ml; p  0.001) was observed. CONCLUSIONS: Direct 
monthly supply of HAART medications at the HIV center is a very low cost mode 
which signiﬁcantly improves patient’s adherence as well as immunological and viro-
logical outcome.
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OBJECTIVES: Palivizumab has been shown to reduce the number of respiratory syn-
cytial virus (VSR) related hospitalizations in preterm infants and patients with bron-
chopulmonary dysplasia or congestive heart disease. It is widely used but its high price 
raises concerns about its cost-effectiveness. The aim of this study was to systematically 
review economic evaluations (EE) of palivizumab in high-risk patients. METHODS: 
A comprehensive search for literature on the cost-effectiveness of palivizumab versus 
no prophylaxis was conducted. Bibliographic databases were searched from September 
2001 to February 2008. Additional relevant studies were identiﬁed from manual 
searches. Only studies published in English and Spanish were included. Quality was 
assessed using the Drummond criteria for EE. Two independent reviewers scrutinized 
retrieved references and assessed the quality of the studies. RESULTS: Twenty refer-
ences were included, representing a total of 32 EE: 20 cost-effectiveness analyses 
(CEA), 10 cost-utility analyses (CUA) and 2 cost-beneﬁt analyses (CBA). Quality was 
variable. Populations varied widely with some studies including all high-risk patients 
and others focusing on speciﬁc subgroups. Results were reported as incremental cost-
effectiveness ratios in terms of cost per hospitalization prevented, life-year gained or 
quality-adjusted life-year in all CEA and ACU and as cost-beneﬁt ratios in CBA. Esti-
mates of incremental ratios ranged from cost savings to incremental costs of a high 
order of magnitude. Assumptions on hospitalization rates in intensive care units, 
mortality and long-term consequences due to RSV infections, as well as acquisition 
cost of palivizumab seem to be related with more favourable ratios. A tendency for 
better results was also observed in studies receiving ﬁnancial support from the manu-
facturer. CONCLUSIONS: A true determination of cost-effectiveness of palivizumab 
is difﬁcult. However, costs of palivizumab seem to exceed potential cost-saving from 
reduced admission rates and might only prove to be cost-effective in a small subset of 
very high risk patients.
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THE ROLE OF ECONOMIC EVALUATION IN THE HEALTH 
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LEARNED FROM FINLAND
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OBJECTIVES: The aim of economic evaluation (EE) is to provide information to help            
decision makers maximize health beneﬁts with given resources or advise how to attain 
given health targets efﬁciently in society. We examined the role and weight of EE in 
the HTA of vaccines in Finland and explored how EEs have and should have been 
conducted. METHODS: The methods and perspective of national EEs related to         
rotavirus and pneumococcal conjugate vaccination programs were evaluated. An 
ofﬁcial call for a rotavirus vaccination tender, competitive bidding process and tender 
decision-making criteria were explored. RESULTS: EE can have a crucial role when       
a new vaccine is considered for inclusion in a national vaccination program, which is 
necessary before a tender call for bids can be given. However, for tenders the pre-
dominant decision-making criterion seemed to be cost per vaccine. EE seemed to be 
conducted using a pair-wise comparison instead of multiple comparisons (i.e. different 
vaccines for a certain disease are compared only to no vaccination strategy). Advanced 
methods to characterize uncertainty, such as cost-effectiveness acceptability frontiers 
and value-of-information analyses, have not been applied. Also, no speciﬁc cost-effec-
tiveness threshold for new vaccines has been set in Finland although international 
references and Finnish home dialysis and bypass surgery thresholds have been cited 
in the evaluation reports. However, the literature revealed that setting a threshold may 
be impossible. Thus, we present an ideal EE process that enables value-based threshold 
pricing for manufacturers and decisions that can lead to efﬁciency. CONCLUSIONS: 
There is a discrepancy between the scientiﬁc principles and objectives of EE and real 
life in terms of national EEs of vaccines and tender calls in Finland. The current 
practice does not necessarily lead to optimal decisions based on cost-effectiveness. 
Particularly, multiple comparisons with valid prices should be encouraged.
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OBJECTIVES: The aim of the current work is to implement a Markovian-model and 
a Differential Equation Model for simulating the pneumococcal illnesses and estimate 
the possibility of preventing the disease by vaccination of infants with the 7-valent 
serum. Implementing the two models opens the possibility of comparison of both and 
offers better insights on the inﬂuence of non linear effects like herd immunity and 
serotype replacement. METHODS: To assess the epidemiological inﬂuence of pneu-
mococcal infant vaccination using PCV7 in Austria a static Markovian-model and 
ordinary differential equation (ODE) modeling and simulation techniques are used. 
The Markovian model approach was classiﬁed as state of the art using a systematic 
literature review. (334 abstracts, 45 papers in detail) Implementing a model for serious 
diseases (meningitis, septicaemia and bacteraemic pneumonia) based on an infection 
